VanEck Pharmaceutical ETFPPH
PPH
0
Funds holding %
of 7,407 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
15% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 39
11.58% more ownership
Funds ownership: 74.87% [Q3] → 86.45% (+11.58%) [Q4]
7% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 27
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
1% less funds holding
Funds holding: 138 [Q3] → 136 (-2) [Q4]
6% less capital invested
Capital invested by funds: $540M [Q3] → $508M (-$32.3M) [Q4]
71% less call options, than puts
Call options by funds: $1.25M | Put options by funds: $4.37M
Research analyst outlook
We haven’t received any recent analyst ratings for PPH.
Financial journalist opinion
Neutral
Seeking Alpha
5 days ago
PPH: Will Overcome Tariffs, But Competitor Funds Look Stronger
VanEck Pharmaceutical ETF holds a mixed outlook due to high fees and tariff risks, warranting a hold rating despite strong top holdings. PPH's top holdings like Eli Lilly and Johnson & Johnson have diversified revenue streams and U.S. manufacturing investments, mitigating tariff impacts. PPH has underperformed compared to broader healthcare ETFs like VHT and XLV, which offer better diversification and lower expense ratios.
Neutral
Zacks Investment Research
4 weeks ago
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
Looking for broad exposure to the Healthcare - Pharma segment of the equity market? You should consider the VanEck Pharmaceutical ETF (PPH), a passively managed exchange traded fund launched on 12/20/2011.
Neutral
Seeking Alpha
1 month ago
Seeking Stocks With Vitality In The Volatile Healthcare Sector
Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US administration affect healthcare companies?
Neutral
Zacks Investment Research
3 months ago
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
Designed to provide broad exposure to the Healthcare - Pharma segment of the equity market, the VanEck Pharmaceutical ETF (PPH) is a passively managed exchange traded fund launched on 12/20/2011.
Positive
Seeking Alpha
3 months ago
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 billion by 2028. Every year, the FDA and EMA approve dozens of anticancer drugs, so Seeking Alpha readers should be careful when making decisions.
Neutral
CNBC Television
3 months ago
Final Trade: MSTR, PPH, TLT, MCD
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Positive
ETF Trends
3 months ago
PPH Is a Pertinent Healthcare Idea for 2025
The healthcare sector is conspicuous in its absence from this year's bull market for stocks. As of Dec. 17, the S&P Health Care Select Sector Index was higher by just 3.2% since the start of the year compared to a 28.3% gain for the S&P 500.
Neutral
Zacks Investment Research
5 months ago
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
The VanEck Pharmaceutical ETF (PPH) was launched on 12/20/2011, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Pharma segment of the equity market.
Negative
Seeking Alpha
6 months ago
Pharma Stocks Losing Ground After A Remarkable Rally, Downgrading PPH
The VanEck Pharmaceutical ETF has shown strong performance but faces near-term downside risks, prompting a rating downgrade from buy to hold. PPH's valuation has increased significantly, with a high price-to-earnings ratio and concentrated portfolio, particularly in top holdings like LLY and NVO. Technical indicators suggest bearish momentum, with potential support in the mid-$80s, making it a favorable risk/reward buy on further pullback.
Positive
ETF Trends
6 months ago
Healthcare ETFs Starting to Look Healthy
The healthcare sector hasn't been a bad performer, per se. Year-to-date, the S&P Health Care Select Sector Index is up 13.1%, but that lags the S&P 500 by 800 basis points, confirming investors have cause to be frustrated with blue-chip pharmaceuticals and biotechnology equities.
Charts implemented using Lightweight Charts™